Sublingual Film is fastest growing segment fueling the growth of...

Sublingual Film is fastest growing segment fueling the growth of Buprenorphine Market

Postado 2023-11-27 12:00:27

Market Overview:
Buprenorphine is commonly used as a medication-assisted treatment for opioid use disorder. It helps reduce cravings and withdrawal symptoms without causing the euphoric feeling or toxicity associated with full opioid agonists. The growing prevalence of opioid addiction worldwide coupled with supportive government initiatives regarding medication-assisted therapies are fueling the demand for buprenorphine products globally.

Market key trends:
Sublingual film formulation of The Buprenorphine Market Demand has emerged as the fastest growing segment in the market. Compared to sublingual tablets, films have better patient adherence due to convenience of administration without water. Also, films provide a precise dose, instant onset of action and controlled dissolution profile. Major players are focusing on developments and launches of innovative sublingual films containing buprenorphine for both mono and combinational therapies. For instance, in 2019, Indivior launched Sublocade, the first once-monthly buprenorphine extended-release injection to treat moderate-to-severe OUD. Similarly, in 2020, Braeburn received FDA approval for CAM2038, a weekly and monthly subdermal buprenorphine implant for moderate-to-severe OUD.
Segment Analysis
Buprenorphine can be broadly classified into two types: Buprenorphine injections and Buprenorphine tablets. Among these, Buprenorphine tablets dominate the market and accounts for over 70% of the overall market share due to high precision dosage and ease of administration. Several sublingual and buccal films have also entered the market in recent years owing to better patient compliance.

Key Takeaways
The global Buprenorphine market is expected to witness high growth, exhibiting a CAGR of 14% over the forecast period, due to increasing prevalence of opioid dependence worldwide. North America currently dominates the Buprenorphine market and is expected to continue its dominance over the forecast period owing to rising government initiatives for treatment of substance abuse disorders in the region. The Asia Pacific region is expected to be the fastest growing market for Buprenorphine due to improving healthcare infrastructure and growing awareness.

Key players operating in the Buprenorphine market are Siegfried, Sanofi, Johnson Matthey, Mallinckrodt, Noramco, Unichem Laboratories, Arevipharma GmbH, Resonance-labs, Sun Pharmaceutical Industries Ltd., Rusan Pharma, Micro Orgo Chem, and Faran Shimi Pharmaceutical Co. Siegfried dominates the overall market with over 35% share owing to its wide product portfolio and established distribution network across regions.